US$ 29.11
glp-1 agonists and muscle loss Glucagon-like peptide-1 receptor: mechanisms advances in therapy Skeletal muscle mass accounts for
Description
Conclusion Emerging evidence underscores the cardioprotective effects of GLP-1RAs, which make them potentially useful for different subpopulations of patients with cardiovascular diseases, including those with HFpEF
Elovainio M, Shipley MJ, Ferrie JE, Gimeno D, Vahtera J, Marmot MG, et al

Tirzepatide was approved under the brand name Mounjaro for T2D in May 2022

The overall molecular properties of orforglipron, molecular weight approximately 529 Da, moderate lipophilicity (cLogP approximately 3.5), and limited hydrogen bond donors and acceptors, place it within the "drug-like" chemical space defined by Lipinski's Rule of Five, although at the upper boundary

Effect of GLP1 agonists on reproduction

CRD42021283449
